Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $0.83 in the prior trading day, Alx Oncology Holdings Inc (NASDAQ: ALXO) closed at $0.78, down -5.60%. In other words, the price has decreased by -$5.60 from its previous closing price. On the day, 0.63 million shares were traded. ALXO stock price reached its highest trading level at $0.87 during the session, while it also had its lowest trading level at $0.772.
Ratios:
Our goal is to gain a better understanding of ALXO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.26 and its Current Ratio is at 7.26. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on March 06, 2025, Upgraded its rating to Buy and sets its target price to $3 from $2 previously.
On December 19, 2024, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $12 to $2.
Stifel Downgraded its Buy to Hold on March 08, 2024, whereas the target price for the stock was revised from $10 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 19 ’25 when Pinto Shelly sold 550 shares for $1.15 per share. The transaction valued at 633 led to the insider holds 87,352 shares of the business.
Pons Jaume sold 1,326 shares of ALXO for $1,525 on Feb 19 ’25. The PRESIDENT & CSO now owns 579,388 shares after completing the transaction at $1.15 per share. On Feb 19 ’25, another insider, Lettmann Jason, who serves as the CHIEF EXECUTIVE OFFICER of the company, sold 2,159 shares for $1.15 each. As a result, the insider received 2,483 and left with 170,270 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALXO now has a Market Capitalization of 41831780 and an Enterprise Value of -68947184.
Stock Price History:
The Beta on a monthly basis for ALXO is 1.09, which has changed by -0.9321799 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, ALXO has reached a high of $17.83, while it has fallen to a 52-week low of $0.83. The 50-Day Moving Average of the stock is -39.69%, while the 200-Day Moving Average is calculated to be -72.93%.
Shares Statistics:
The stock has traded on average 1.23M shares per day over the past 3-months and 2320670 shares per day over the last 10 days, according to various share statistics. A total of 53.05M shares are outstanding, with a floating share count of 34.04M. Insiders hold about 36.24% of the company’s shares, while institutions hold 56.29% stake in the company. Shares short for ALXO as of 1740700800 were 5887074 with a Short Ratio of 4.77, compared to 1738281600 on 5988123. Therefore, it implies a Short% of Shares Outstanding of 5887074 and a Short% of Float of 18.94.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Alx Oncology Holdings Inc (ALXO) is currently attracting attention from 1.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.31 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$1.14 and -$1.14 for the fiscal current year, implying an average EPS of -$1.14. EPS for the following year is -$0.9, with 1.0 analysts recommending between -$0.9 and -$0.9.
